Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 13/20 | 0.58 |
| ▸ | GSPT1 | P15170 | 4/20 | 0.58 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.58 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | CSNK1A1 | P48729 | 7/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | IKZF2 | Q9UKS7 | 9/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL60743 | 0.93 | CRBN (0.67) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL1413830 | 0.82 | CRBN (0.71) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL13815869 | 0.82 | CRBN (0.60) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL4450381 | 0.80 | CRBN (0.55) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL16301126 | 0.80 | CRBN (0.66) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL17495166 | 0.79 | ESR2 (0.44) | CRBNGSPT1DDB1IKZF3ESR2 | |
| SCHEMBL28881284 | 0.78 | CRBN (0.69) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL28881359 | 0.78 | CRBN (0.69) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL4450784 | 0.77 | CRBN (0.60) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL27262311 | 0.77 | CRBN (0.60) | CRBNGSPT1DDB1IKZF3CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10034872-B2 | Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies | CELGENE CORPORATION (US) | 2018-07-31 | — | — | US | disclosed |
| US-9550766-B2 | Isoindoline compounds and methods of their use | CELGENE CORPORATION (US) | 2017-01-24 | — | — | US | disclosed |
| US-20160115161-A1 | ISOINDOLINE COMPOUNDS AND METHODS OF THEIR USE | CELGENE CORPORATION | 2016-04-28 | — | — | US | disclosed |
| US-9227954-B2 | Isoindoline compounds and methods of their use | CELGENE CORPORATION (US) | 2016-01-05 | — | — | US | disclosed |
| US-20140314752-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-10-23 | — | — | US | disclosed |
| US-20130045976-A1 | ISOINDOLINE COMPOUNDS AND METHODS OF THEIR USE | CELGENE CORPORATION (US) | 2013-02-21 | — | — | US | disclosed |
| US-20120252843-A1 | ISOINDOLINE COMPOUNDS AND METHODS OF THEIR USE | CELGENE CORPORATION | 2012-10-04 | — | — | US | disclosed |
| US-8222249-B2 | Isoindoline compounds and methods of their use | CELGENE CORPORATION (US) | 2012-07-17 | — | — | US | disclosed |
| US-20120122865-A1 | ISOINDOLINE COMPOUNDS AND METHODS OF THEIR USE | CELGENE CORPORATION | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140314752-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | MTOR, ULK1, RICTOR | CRBN 869/4885GSPT1 861/4885DDB1 820/4885 |
| US-20120252843-A1 | ISOINDOLINE COMPOUNDS AND METHODS OF THEIR USE | CPT1A, CYP11B2, NPC1 | CRBN 4221/4885GSPT1 2532/4885DDB1 1898/4885 |
| US-20120122865-A1 | ISOINDOLINE COMPOUNDS AND METHODS OF THEIR USE | CPT1A, CYP11B2, NPC1 | CRBN 4221/4885GSPT1 2532/4885DDB1 1898/4885 |
| US-20130045976-A1 | ISOINDOLINE COMPOUNDS AND METHODS OF THEIR USE | CPT1A, CYP11B2, NPC1 | CRBN 4221/4885GSPT1 2532/4885DDB1 1898/4885 |
| US-20160115161-A1 | ISOINDOLINE COMPOUNDS AND METHODS OF THEIR USE | CPT1A, CYP11B2, NPC1 | CRBN 4221/4885GSPT1 2532/4885DDB1 1898/4885 |
| US-10034872-B2 | Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies | CHP1, MCL1, CSGALNACT1 | CRBN 54/4885GSPT1 1087/4885DDB1 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.